LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 46

Search options

  1. Article: Editorial: Precision medicine for acute myeloid leukemia.

    Marconi, Giovanni / Guolo, Fabio / Nanni, Jacopo / Papayannidis, Cristina

    Frontiers in oncology

    2023  Volume 13, Page(s) 1233757

    Language English
    Publishing date 2023-07-25
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1233757
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

    Guolo, Fabio / Cerchione, Claudio / Vernarecci, Chiara / Isidori, Alessandro

    Frontiers in oncology

    2022  Volume 12, Page(s) 1020185

    Language English
    Publishing date 2022-09-09
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.1020185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Harnessing Immune Response in Acute Myeloid Leukemia.

    Riva, Carola / Vernarecci, Chiara / Minetto, Paola / Goda, Rayan / Greppi, Marco / Pesce, Silvia / Chies, Maria / Zecchetti, Giada / Ferro, Beatrice / Maio, Elena / Cea, Michele / Lemoli, Roberto Massimo / Marcenaro, Emanuela / Guolo, Fabio

    Journal of clinical medicine

    2023  Volume 12, Issue 18

    Abstract: Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory ( ... ...

    Abstract Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among the most innovative therapeutic options, cellular therapy has shown great results in different hematological malignancies such as acute lymphoblastic leukemia and lymphomas, with several products already approved for clinical use. However, despite the great interest in also expanding the application of these new treatments to R/R AML, no product has been approved yet for clinical application. Furthermore, cellular therapy could indeed represent a powerful tool and an appealing alternative to allogeneic hematopoietic stem cell transplantation for ineligible patients. In this review, we aim to provide an overview of the most recent clinical research exploring the effectiveness of cellular therapy in AML, moving from consolidated approaches such as post- transplant donor's lymphocytes infusion, to modern adoptive immunotherapies such as alloreactive NK cell infusions, engineered T and NK cells (CAR-T, CAR-NK) and novel platforms of T and NK cells engaging (i.e., BiTEs, DARTs and ANKET
    Language English
    Publishing date 2023-09-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12185824
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma.

    Gelli, Elisa / Soncini, Debora / Becherini, Pamela / Martinuzzi, Claudia / Todoerti, Katia / Cagnetta, Antonia / Aquino, Sara / Guolo, Fabio / Miglino, Maurizio / Bruzzone, Santina / Nencioni, Alessio / Neri, Antonino / Lemoli, Roberto M / Cea, Michele

    Blood advances

    2023  Volume 7, Issue 14, Page(s) 3472–3478

    MeSH term(s) Humans ; Spliceosomes/genetics ; Multiple Myeloma/genetics ; Sirtuins
    Chemical Substances Sirtuins (EC 3.5.1.-) ; SIRT6 protein, human (EC 3.5.1.-)
    Language English
    Publishing date 2023-03-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022009035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey.

    Valentini, Caterina Giovanna / Piciocchi, Alfonso / Facchetti, Fabio / Guolo, Fabio / Pulsoni, Alessandro / Vignetti, Marco / Pagano, Livio

    Blood advances

    2021  Volume 5, Issue 24, Page(s) 5608–5611

    MeSH term(s) Dendritic Cells ; Hematologic Neoplasms/epidemiology ; Humans
    Language English
    Publishing date 2021-10-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2021005802
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia.

    Minetto, Paola / Guolo, Fabio / Miglino, Maurizio

    Leukemia research

    2016  Volume 43, Page(s) 49–50

    MeSH term(s) Female ; Graft vs Leukemia Effect ; Humans ; Leukemia, Myelomonocytic, Chronic/mortality ; Leukemia, Myelomonocytic, Chronic/surgery ; Male
    Language English
    Publishing date 2016-04
    Publishing country England
    Document type Comment ; Editorial
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2016.01.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.

    Meazza, Raffaella / Ruggeri, Loredana / Guolo, Fabio / Minetto, Paola / Canevali, Paolo / Loiacono, Fabrizio / Ciardelli, Sara / Bo, Alessandra / Luchetti, Silvia / Serio, Alberto / Zannoni, Letizia / Retière, Christelle / Colomar-Carando, Natalia / Parisi, Sarah / Curti, Antonio / Lemoli, Roberto M / Pende, Daniela

    Frontiers in immunology

    2023  Volume 14, Page(s) 1111419

    Abstract: Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from ...

    Abstract Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were infused. The aim of this study was comparing two approaches to define the size of alloreactive NK cells in haploidentical donors for AML patients recruited in two clinical trials with the acronym "NK-AML" (NCT03955848), and "MRD-NK". The standard methodology was based on the frequency of NK cell clones capable of lysing the related patient-derived cells. The alternative approach consisted of the phenotypic identification of freshly derived NK cells expressing, as inhibitory receptors, only the inhibitory KIR(s) specific for the mismatched KIR-Ligand(s) (HLA-C1, HLA-C2, HLA-Bw4). However, in KIR2DS2
    MeSH term(s) Aged ; Humans ; Donor Selection ; Leukocytes, Mononuclear ; Immunotherapy, Adoptive ; Reproducibility of Results ; Leukemia, Myeloid, Acute/therapy ; Killer Cells, Natural ; Clone Cells
    Language English
    Publishing date 2023-02-14
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1111419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents

    Becherini, Pamela / Soncini, Debora / Ravera, Silvia / Gelli, Elisa / Martinuzzi, Claudia / Giorgetti, Giulia / Cagnetta, Antonia / Guolo, Fabio / Ivaldi, Federico / Miglino, Maurizio / Aquino, Sara / Todoerti, Katia / Neri, Antonino / Benzi, Andrea / Passalacqua, Mario / Nencioni, Alessio / Perrotta, Ida / Gallo Cantafio, Maria Eugenia / Amodio, Nicola /
    De Flora, Antonio / Bruzzone, Santina / Lemoli, Roberto M. / Cea, Michele

    Antioxidants. 2023 Feb. 15, v. 12, no. 2

    2023  

    Abstract: Cancer cells fuel growth and energy demands by increasing their NAD⁺ biosynthesis dependency, which therefore represents an exploitable vulnerability for anti-cancer strategies. CD38 is a NAD⁺-degrading enzyme that has become crucial for anti-MM ... ...

    Abstract Cancer cells fuel growth and energy demands by increasing their NAD⁺ biosynthesis dependency, which therefore represents an exploitable vulnerability for anti-cancer strategies. CD38 is a NAD⁺-degrading enzyme that has become crucial for anti-MM therapies since anti-CD38 monoclonal antibodies represent the backbone for treatment of newly diagnosed and relapsed multiple myeloma patients. Nevertheless, further steps are needed to enable a full exploitation of these strategies, including deeper insights of the mechanisms by which CD38 promotes tumorigenesis and its metabolic additions that could be selectively targeted by therapeutic strategies. Here, we present evidence that CD38 upregulation produces a pervasive intracellular-NAD⁺ depletion, which impairs mitochondrial fitness and enhances oxidative stress; as result, genetic or pharmacologic approaches that aim to modify CD38 surface-level prime MM cells to NAD⁺-lowering agents. The molecular mechanism underlying this event is an alteration in mitochondrial dynamics, which decreases mitochondria efficiency and triggers energetic remodeling. Overall, we found that CD38 handling represents an innovative strategy to improve the outcomes of NAD⁺-lowering agents and provides the rationale for testing these very promising agents in clinical studies involving MM patients.
    Keywords biosynthesis ; carcinogenesis ; energy ; enzymes ; fuels ; mitochondria ; myeloma ; oxidative stress ; therapeutics
    Language English
    Dates of publication 2023-0215
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article ; Online
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox12020494
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD

    Becherini, Pamela / Soncini, Debora / Ravera, Silvia / Gelli, Elisa / Martinuzzi, Claudia / Giorgetti, Giulia / Cagnetta, Antonia / Guolo, Fabio / Ivaldi, Federico / Miglino, Maurizio / Aquino, Sara / Todoerti, Katia / Neri, Antonino / Benzi, Andrea / Passalacqua, Mario / Nencioni, Alessio / Perrotta, Ida / Gallo Cantafio, Maria Eugenia / Amodio, Nicola /
    De Flora, Antonio / Bruzzone, Santina / Lemoli, Roberto M / Cea, Michele

    Antioxidants (Basel, Switzerland)

    2023  Volume 12, Issue 2

    Abstract: Cancer cells fuel growth and energy demands by increasing their ... ...

    Abstract Cancer cells fuel growth and energy demands by increasing their NAD
    Language English
    Publishing date 2023-02-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox12020494
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.

    Guolo, Fabio / Minetto, Paola / Clavio, Marino / Miglino, Maurizio / Lemoli, Roberto Massimo / Gobbi, Marco

    Bioscience trends

    2017  Volume 11, Issue 1, Page(s) 110–114

    Abstract: Acute Myeloid Leukemia (AML) is the commonest form of leukemia in the adults, with an incidence of 3-4 cases per 100,000 people/year. After the first description of the effective cytarabine + antracycline (3+7) induction regimen, in the last 3 decades, ... ...

    Abstract Acute Myeloid Leukemia (AML) is the commonest form of leukemia in the adults, with an incidence of 3-4 cases per 100,000 people/year. After the first description of the effective cytarabine + antracycline (3+7) induction regimen, in the last 3 decades, no effective targeted drug has been included in the standard treatment of AML. Many efforts of modifying 3+7 adding a third drug or increasing the dose of anthracycline, cytarabine or both did not lead to substantial improvements, mainly due to increased toxicity. Many in vitro and in vivo evidences suggested that fludarabine may increase efficacy of cytarabine through a synergistic effect. Considering the continuous improvements in supportive care and management of infectious complications the feasibility of more intensive induction strategies have increased and a renewed interest in fludarabine-containing induction strategies arose. The recent MRC AML 15 trial has shown that a fludarabine-containing induction, FLAG-Ida, resulted superior to conventional 3+7 in terms of complete remission rates, relapse incidence and survival, although only a minority of patients could complete the whole planned consolidation program due to an excessive hematological toxicity. Our group recently published a 10-year experience with a fludarabine-containing induction that slightly differed from the MRC one and resulted in good efficacy and higher feasibility. In this commentary we review the major evidences supporting the employ of a fludarabine-containing induction in AML, and discuss the future perspectives.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Consolidation Chemotherapy ; Cytarabine/therapeutic use ; Dose-Response Relationship, Drug ; Humans ; Idarubicin/therapeutic use ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/drug therapy ; Stem Cell Transplantation ; Treatment Outcome ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use ; Young Adult
    Chemical Substances Cytarabine (04079A1RDZ) ; Vidarabine (FA2DM6879K) ; fludarabine (P2K93U8740) ; Idarubicin (ZRP63D75JW)
    Language English
    Publishing date 2017-03-22
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 2543899-2
    ISSN 1881-7823 ; 1881-7815
    ISSN (online) 1881-7823
    ISSN 1881-7815
    DOI 10.5582/bst.2016.01221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top